PolyMedica settles Medicare over-billing charges
This article was originally published in The Gray Sheet
Executive Summary
Tentative settlement with the Department of Justice will include a $35 mil. payment and a corporate integrity agreement without admission of wrongdoing, the firm says. The deal follows a three-year DoJ investigation into the company's Medicare billing and claims documentation practices. "It's important to note the agreements are still being negotiated and are subject to approval by the OIG and DoJ," PolyMedica Chairman Samuel Shanaman says in a release. The diabetes and respiratory product firm notes that the U.S. Attorney's Office for the Southern District of Florida "will not bring criminal charges against the company" (1"The Gray Sheet" Feb. 16, 2004, p. 12)...
You may also be interested in...
PolyMedica Explains Medicare Over-Billing, Accrues Reserves For Repayment
PolyMedica will seek growth through acquisitions to offset an average 3% reduction in reimbursement rates for its diabetes products that will become effective in 2005 under the recent Medicare law
More Heartmate Troubles For Abbott. Latest Recall Includes 14 Deaths
Abbott initiated a recall in February of thousands of Heartmate devices due to a system obstruction that can result in serious health outcomes, including death. The FDA has now designated the recall as class I.
‘Unbalanced’ EU HTA Timelines Exacerbated By Rare Disease & Cancer Drugs
As it stands, drugmakers will have just 90 days to prepare their dossiers for EU-wide joint clinical assessments under the new Health Technology Assessment Regulation. Market access experts from EFPIA tell the Pink Sheet that this short deadline could delay patient access to complex medicines, such as innovative cancer drugs.